Maguire seems to have given up on Pagoclone:
A few years back Maguire and his team tested a drug that showed great promise: Pagoclone, the only drug ever designed specifically to help stuttering [ERROR OF AUTHOR], eased anxiety among subjects and helped them speak more fluently, without any major side effects. But it hasn't been approved by the Food and Drug Administration, and it won't be any time soon, Maguire said.And now he seems to believe in Asenapine:
... and he may have finally found the solution: a drug that's going through a trial at UC IrvineAnd more details:
under his supervision. The medication, which is already in use to help people with bipolar disorder and schizophrenia, is called Asenapine.
"I’ve actually measured it, and before it was 80 perent worse than it is now," said Maguire, who has been on the drug for 8-9 months. "I never even used the phonme I tried to avoid it. Now I’m a professor, and I lecture in front of students, so I’m actually able to get through it. It’s really helped me a ton, and if I were to stop it, after three days my speech would return to where it was."
Asenapine inhibits this dopamine-bombardment and seems to give stutterers great improvement. A bonus is that the drug, which is made by Merck, already been approved by the FDA for mental illness. Another bonus is that its side effects -- which could include weight gain and sexual dysfunction -- aren't as severe as with dopamine-blockers that have come before it.We have been here before with Pagoclone. We need to be skeptical again, and wait for serious results. The advantage is that Asenapine is already approved for other disorders. I am a bit confused that it's a Phase IV. I thought that this is a trial for 1000s of users to detect rare side effects.
"I think Asenapine is going to be better" than Pagoclone, said Maguire, who's nearly ready to begin a Phase IV trial for Asenapine at UCI.
So what about Pagoclone? The results have not been made public, and the only official note is that one of Endo's website of the discontinuation. This is a brilliant example of the publication and survival bias. That's why we always see the positive research outcomes, because NO-ONE publishes the bad ones. I sincerely hope that Maguire and others are actually publishing the trial outcome. Especially the result of the placebo group should be very interesting, as it provides a base line to any stuttering treatment.